FDA supplemental approval: Hydrocodone Bitartrate AND Acetaminophen (REMS)

AI Summary

The FDA approved a supplemental REMS application for hydrocodone bitartrate and acetaminophen combination tablets in three formulations (5 mg, 7.5 mg, and 10 mg hydrocodone with 300 mg acetaminophen) on 18 June 2026. This regulatory action establishes or modifies risk management requirements for the product but does not itself contain clinical trial data, efficacy results, or safety outcomes.

Plain-language summary

FDA supplemental approval of a REMS (Risk Evaluation and Mitigation Strategy) for hydrocodone bitartrate and acetaminophen combination tablets; this is a regulatory action establishing safety oversight requirements, not a clinical efficacy or safety trial.

Reported figures

Quoted from the source exactly as published.

Clinical bottom line

This regulatory approval action does not directly impact clinical practice decisions regarding efficacy or safety outcomes. Clinicians should consult the REMS requirements and product labeling for prescribing, dispensing, and patient counselling obligations associated with this opioid combination product.

Caveats

• This record does not contain clinical trial results, efficacy data, or comparative safety outcomes.
• The record does not specify what REMS requirements were imposed or modified.
• No patient population, sample size, or clinical endpoints are reported.
• This is a generic/abbreviated application (ANDA); original approval history and clinical development data are not provided in this record.

Evidence assessment

Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.

Follow from this

Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.